TP-03

DRUG2 trials

Sponsors

Tarsus Pharmaceuticals, Inc.

Conditions

BlepharitisDemodex InfestationMeibomian Gland Dysfunction

Phase 2

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

CompletedNCT05454956

Tarsus Pharmaceuticals, Inc.Blepharitis, Demodex Infestation, Meibomian Gland Dysfunction

Start: 2022-08-03End: 2023-05-18Updated: 2025-10-01

Phase 3

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

CompletedNCT04784091

Tarsus Pharmaceuticals, Inc.Blepharitis

Start: 2021-04-29End: 2022-05-09Updated: 2023-12-21

Related Papers

Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials.

2025-01-281 citations